The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring

Thrombosis Research

Volumn 136, Issue 5, 2015, Pages 851-854

  Mannucci, P M ^a   Cugno, M ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ADAMTS13; Complement activation; Eculizumab; Hemolytic uremic syndrome; Plasma therapy; Thrombotic thrombocytopenic purpura

Indexed keywords

CREATININE; ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

COMPLEMENT SYSTEM; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; LABORATORY DIAGNOSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; GENETICS; LABORATORY; METABOLISM; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; HUMANS; LABORATORIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84948712798     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.09.007     Document Type: Review

References (35)

1. J.N. George, and C.M. Nester Syndromes of thrombotic microangiopathy N. Engl. J. Med. 371 2014 654 666
2. P.M. Mannucci Understanding organ dysfunction in thrombotic thrombocytopenic purpura Intensive Care Med. 41 2015 715 718
3. G.A. Rock, K.H. Shumak, N.A. Buskard, V.S. Blanchette, J.G. Kelton, R.C. Nair, et al. Canadian Apheresis Study Group Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura N. Engl. J. Med. 325 1991 393 397
4. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, B. Brenner, and et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N. Engl. J. Med. 339 1998 1578 1584
5. H.M. Tsai, and E.C. Lian Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N. Engl. J. Med. 339 1998 1585 1594
6. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N. Engl. J. Med. 361 2009 1676 1687
7. J. Zuber, F. Fakhouri, L.T. Roumenina, C. Loirat, and V. Fremeaux-Bacchi Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol. 8 2012 643 657
8. C.M. Legendre, C. Licht, P. Muus, L.A. Greenbaum, S. Babu, C. Bedrosian, and et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N. Engl. J. Med. 368 2013 2169 2181
9. F. Peyvandi for the TITAN Investigators C. Duby Caplacizumab, anti-VWF nanobody potentially changing the treatment paradigm in thrombotic thrombocytopenic purpura: results of the TITAN trial Blood ASH Abstract Book Abstr. n. 229 2014
10. P. Knobl, B. Jilma, J.C. Gilbert, R.M. Hutabarat, P.G. Wagner, and P. Jilma-Stohlawetz Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura Transfusion 49 2009 2181 2185
11. S.R. Cataland, F. Peyvandi, P.M. Mannucci, B. Lammle, J.A. Kremer Hovinga, S.J. Machin, and et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura Am. J. Hematol. 87 2012 430 432
12. M. Scully, M. Gattens, K. Khair, and R. Liesner The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura Br. J. Haematol. 135 2006 101 104
13. F. Peyvandi, P.M. Mannucci, C. Valsecchi, S. Pontiggia, C. Farina, and A.D. Retzios ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates Am. J. Hematol. 88 2013 895 898
14. G.G. Levy, W.C. Nichols, E.C. Lian, T. Foroud, J.N. McClintick, B.M. McGee, and et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura Nature 413 2001 488 494
15. L.A. Lotta, H.M. Wu, I.J. Mackie, M. Noris, A. Veyradier, M.A. Scully, and et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura Blood 120 2012 440 448
16. M. Rieger, P.M. Mannucci, J.A. Kremer Hovinga, A. Herzog, G. Gerstenbauer, C. Konetschny, and et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases Blood 106 2005 1262 1267
17. M. Hie, J. Gay, L. Galicier, F. Provot, C. Presne, P. Poullin, and et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura Blood 124 2014 204 210
18. S.K. Vesely, J.N. George, B. Lammle, J.D. Studt, L. Alberio, M.A. El-Harake, and et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood 102 2003 60 68
19. P.M. Mannucci, M.T. Canciani, I. Forza, F. Lussana, A. Lattuada, and E. Rossi Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood 98 2001 2730 2735
20. P. Coppo, D. Bengoufa, A. Veyradier, M. Wolf, A. Bussel, G.A. Millot, and et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement Medicine (Baltimore) 83 2004 233 244
21. P. Coppo, M. Schwarzinger, M. Buffet, A. Wynckel, K. Clabault, C. Presne, and et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience PLoS One 5 2010 e10208
22. M.J. Bentley, C.M. Lehman, R.C. Blaylock, A.R. Wilson, and G.M. Rodgers The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange Transfusion 50 2010 1654 1664
23. S.R. Cataland, S. Yang, and H.M. Wu The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies Br. J. Haematol. 157 2012 501 503
24. S.R. Cataland, and H.M. Wu How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome Blood 123 2014 2478 2484
25. M. Lemaire, V. Fremeaux-Bacchi, F. Schaefer, M. Choi, W.H. Tang, Q.M. Le, and et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Nat. Genet. 45 2013 531 536
26. C. Loirat, and V. Fremeaux-Bacchi Atypical hemolytic uremic syndrome Orphanet. J. Rare Dis. 6 2011 60
27. E. Bresin, E. Rurali, J. Caprioli, P. Sanchez-Corral, V. Fremeaux-Bacchi, C.S. Rodriguez de, and et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype J. Am. Soc. Nephrol. 24 2013 475 486
28. E. Gavriilaki, X. Yuan, Z. Ye, A.J. Ambinder, S.P. Shanbhag, M.B. Streiff, and et al. Modified Ham test for atypical hemolytic uremic syndrome Blood 125 2015 3637 3646
29. J.E. Sadler Atypical HUS, may become a diagnosis of inclusion Blood 125 2015 3525 3526
30. S.R. Cataland, V.M. Holers, S. Geyer, S. Yang, and H.M. Wu Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP Blood 123 2014 3733 3738
31. E.B. Volokhina, D. Westra, T.J. van der Velden, N.C. van de Kar, T.E. Mollnes, and L.P. van den Heuvel Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission Clin. Exp. Immunol 181 2015 306 313
32. M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla, E. Bresin, and et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy Blood 124 2014 1715 1726
33. R. Peffault de Latour, V. Fremeaux-Bacchi, R. Porcher, A. Xhaard, J. Rosain, D.C. Castaneda, and et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab Blood 125 2015 775 783
34. M. Cugno, S. Tedeschi, and G. Ardissino Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment J. Thromb. Haemost. 13 2015 485 486
35. M. Cugno, R. Gualtierotti, I. Possenti, S. Testa, F. Tel, S. Griffini, and et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome J. Thromb. Haemost. 12 2014 1440 1448